Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor Maintenance in Advanced or Recurrent Endometrial Cancer
NCT03555422Phase 3Completed
- Sponsor
- Karyopharm Therapeutics Inc.
- Start
- Jan 2018
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 10
01
Overview
A Phase 3 trial of selinexor in endometrial cancer (EC), sponsored by Karyopharm Therapeutics Inc.. Started Jan 2018; status: completed.
02
Drugs
selinexor
03
Conditions
endometrial cancer (EC)
Beyond the preview
Go deeper on NCT03555422.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03555422.